Top image

Our Research

Here you'll find information about our Flagship programs and other projects. Use the filters below to display research of interest using one of the three categories.
  • T2,T3 | Flagship 2 Pilot and Seed
    Body composition changes in cancer patients during chemotherapy
    Chemotherapy dosing is generally determined by a patient's height and weight. This does not account for their body composition and can be inaccurate, particularly in people who are obese or un...
    Personalised medicineNew therapies and diagnosticsColorectal cancer
  • T1,T2 | Flagship 2 Pilot and Seed
    Systematic effects of Gioblastoma multiforme (GBM) and GBM-released extracellular vesicles on immune suppression: implications for dendritic cell-based vaccine therapy against GBM
    Despite recent improvements in cancer therapies, the median survival for patients with brain tumours is only 15 months. We need to urgently develop better treatment options. Anti-tumour vaccin...
    Dendritic cell
  • T2,T3 | Flagship 2 Pilot and Seed
    Relook Laparoscopy for Peritoneal Surface Disease (ReLaPSed) Trial
    Pilot and Seed Funding Awarded: CIA: Cherry Koh Member Group: Royal Prince Alfred Hospital Year and Duration: 2018 for 15 months Amount: $50,000
    Colorectal cancer
  • T1,T2 | Flagship 2 Pilot and Seed
    Understanding the Body’s Response to Cancer Invasion and Progression: Towards Assisting the Body’s Defence System in Fighting Cancer
      Cutaneous squamous cell carcinoma (cSCC; skin cancer) is the most common human cancer with the potential to spread to other parts of the body. Australia has the highest rate of cSCC i...
    Head and Neck Cancer
  • T1 | Flagship 3 Scholarships & Awards
    Thomas Johnson: YB-1: A central player in carcinogenesis and malignant behaviour of malignant pleural mesothelioma
    Malignant pleural mesothelioma (MPM) is an aggressive, asbestos-induced malignancy that responds poorly to treatment. The combination of cisplatin and pemetrexed, which is the current standard...
    BiomarkersMesothelioma
  • T2,T3 | Flagship 3 Scholarships & Awards
    Peey Sei Kok: What are good surrogates for clinically meaningful benefit of new oncology therapies in advanced cancers?
    Robust surrogate endpoints have the potential to reduce the clinical, economic and time burden associated with conducting RCTs and drug development. Our work will feed into future collaborative...
    Phase i/ii clinical trialPhase iii clinical trialDrug developmentClinical Trials
  • T2,T3 | Flagship 3 Scholarships & Awards
    Mohsen Shafiei: Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: A Prospective Observational Study
    The aim of this research project is to determine and compare and pharmacokinetics (PK) of capecitabine and its metabolites in older and younger adults with cancer, and the correlation between ...
    Prospective observational studyDrug developmentTreatment
  • T1,T2,T3 | Flagship Completed Prior June 2016
    Sydney Catalyst Scholarships Awarded pre July 2016
    We aim to encourage training and development of outstanding researchers and clinicians from within Sydney Catalyst units, who have the potential to develop highly significant ca...
    Scholarships
  • T1 | Flagship Completed Prior June 2016
    Lorraine Chantrill and team: IMPACT Trial
    Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) aimed to improve outcomes for patients with advanced pancreas cancer by using molecular analysis of tumor tissue to guide treatment ...
    Personalised medicineClinical TrialsPancreatic cancerTreatment
  • T1 | Sydney Catalyst Supported
    David Croucher: Mapping and manipulating therapeutically induced JNK network architecture to tackle breast cancer chemoresistance
    The current generation of cancer therapies mostly target components of signalling pathways, being either small molecule inhibitors or monoclonal antibodies to cell surface receptors. It is fas...
    Breast CancerChemo resistance